{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T21:29:13Z","timestamp":1785274153600,"version":"3.55.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T00:00:00Z","timestamp":1708905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T00:00:00Z","timestamp":1708905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Direct oral anticoagulants (DOACs) used as an alternative to low-molecular-weight heparin (LMWH) for thromboprophylaxis after cancer surgery for venous thromboembolic events (VTE) remains unclear. This study aimed to investigate the efficacy and safety of DOACs versus LMWH in these patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and methods<\/jats:title>\n                <jats:p>A search of EMBASE, MEDLINE, Cochrane Central Register of Controlled Trials (CENTRAL), and Web of Science was carried out and included all randomized controlled trials (RCTs) and observational studies that directly compared DOACs with LMWH for thromboprophylaxis in patients after cancer surgery through July 25, 2023. The primary efficacy and safety outcomes were VTE, major bleeding, and clinically relevant non-major bleeding (CRNMB) within 30\u00a0days of surgery. The risk of bias was assessed using the Cochrane Risk of Bias 2 (RoB2) tool for RCTs and ROBINS-I tool for non-randomized studies. This study was registered in PROSPERO (CRD42023445386).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We retrieved 5149articles, selected 27 for eligibility, and included 10 studies (three RCTs and seven observational studies) encompassing 3054 patients who underwent postoperative thromboprophylaxis with DOACs (41%) or LMWH (59%). Compared to LMWH thromboprophylaxis, DOACs had a comparable risk of VTE (RR:0.69[95% CI:0.46\u20131.02], I<jats:sup>2<\/jats:sup>\u2009=\u20090%), major bleeding (RR:1.55 [95% CI:0.82\u20132.93], I<jats:sup>2<\/jats:sup>\u2009=\u20092%), and CRNMB (RR, 0.89 [95% CI, 0.4\u20131.98], I<jats:sup>2<\/jats:sup>\u2009=\u200931%) during the 30-day postoperative period. Subgroup analysis of VTE and major bleeding suggested no differences according to study type, extended thromboprophylaxis, tumor types, or different types of DOAC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>DOACs are potentially effective alternatives to LMWH for thromboprophylaxis in patients undergoing cancer surgery, without increasing the risk of major bleeding events.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12957-024-03341-5","type":"journal-article","created":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T03:01:57Z","timestamp":1708916517000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Efficacy and safety of direct oral anticoagulants versus low-molecular-weight heparin for thromboprophylaxis after cancer surgery: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"22","author":[{"given":"Hong","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Ting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-ling","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Jie","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Hua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,26]]},"reference":[{"key":"3341_CR1","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.blre.2018.06.002","volume":"33","author":"N Kekre","year":"2019","unstructured":"Kekre N, Connors JM. Venous thromboembolism incidence in hematologic malignancies. Blood Rev. 2019;33:24\u201332.","journal-title":"Blood Rev"},{"issue":"6","key":"3341_CR2","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1001\/jama.293.6.715","volume":"293","author":"JW Blom","year":"2005","unstructured":"Blom JW, Doggen CJM, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293(6):715\u201322.","journal-title":"JAMA"},{"issue":"3","key":"3341_CR3","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1097\/SLA.0b013e318195c50c","volume":"249","author":"KA Behranwala","year":"2009","unstructured":"Behranwala KA, Williamson RCN. Cancer-associated venous thrombosis in the surgical setting. Ann Surg. 2009;249(3):366\u201375.","journal-title":"Ann Surg"},{"issue":"1","key":"3341_CR4","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12959-023-00530-2","volume":"21","author":"ZK Kirac\u0131","year":"2023","unstructured":"Kirac\u0131 ZK, Yal\u00e7\u0131n N, Cennet \u00d6, Demirkan K, Yorganc\u0131 K. Education and clinical pharmacist-led management strategies for the risk and prophylaxis of venous thromboembolism in general surgery. Thromb J. 2023;21(1):86.","journal-title":"Thromb J"},{"issue":"8","key":"3341_CR5","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1182\/blood.2022015796","volume":"140","author":"C Becattini","year":"2022","unstructured":"Becattini C, Pace U, Pirozzi F, et al. Rivaroxaban vs placebo for extended antithrombotic prophylaxis after laparoscopic surgery for colorectal cancer. Blood. 2022;140(8):900\u20138.","journal-title":"Blood"},{"issue":"20","key":"3341_CR6","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","volume":"36","author":"AM Young","year":"2018","unstructured":"Young AM, Marshall A, Thirlwall J, et al. Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). J Clin Oncol. 2018;36(20):2017\u201323.","journal-title":"J Clin Oncol"},{"issue":"1","key":"3341_CR7","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/rth2.12002","volume":"1","author":"AA Khorana","year":"2017","unstructured":"Khorana AA, McCrae KR, Milentijevic D, et al. Current practice patterns and patient persistence with anticoagulant treatments for cancer-associated thrombosis. Res Pract Thromb Haemost. 2017;1(1):14\u201322.","journal-title":"Res Pract Thromb Haemost"},{"issue":"4","key":"3341_CR8","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692\u20134.","journal-title":"J Thromb Haemost"},{"issue":"8","key":"3341_CR9","first-page":"Cd004318","volume":"8","author":"S Felder","year":"2019","unstructured":"Felder S, Rasmussen MS, King R, et al. Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery. Cochrane Database Syst Rev. 2019;8(8):Cd004318.","journal-title":"Cochrane Database Syst Rev"},{"key":"3341_CR10","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.thromres.2021.06.010","volume":"204","author":"W Knoll","year":"2021","unstructured":"Knoll W, Fergusson N, Ivankovic V, et al. Extended thromboprophylaxis following major abdominal\/pelvic cancer-related surgery: a systematic review and meta-analysis of the literature. Thromb Res. 2021;204:114\u201322.","journal-title":"Thromb Res"},{"issue":"3","key":"3341_CR11","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.ygyno.2020.06.505","volume":"158","author":"ME Ross","year":"2020","unstructured":"Ross ME, Glickman A, Brennecke A, Tayebnejad A, Guntupalli SR. Adherence to postoperative thromboprophylactic medication among gynecologic oncology patients: a subanalysis. Gynecol Oncol. 2020;158(3):754\u20139.","journal-title":"Gynecol Oncol"},{"issue":"22","key":"3341_CR12","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2023.7843","volume":"329","author":"D Schrag","year":"2023","unstructured":"Schrag D, Uno H, Rosovsky R, et al. Direct oral anticoagulants vs low-molecular-weight heparin and recurrent VTE in patients with cancer: a randomized clinical trial. JAMA. 2023;329(22):1924\u201333.","journal-title":"JAMA"},{"issue":"3","key":"3341_CR13","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.chest.2021.09.037","volume":"161","author":"B Planquette","year":"2022","unstructured":"Planquette B, Bertoletti L, Charles-Nelson A, et al. Rivaroxaban vs dalteparin in cancer-associated thromboembolism: a randomized trial. Chest. 2022;161(3):781\u201390.","journal-title":"Chest"},{"issue":"2","key":"3341_CR14","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/jth.14662","volume":"18","author":"RD McBane 2nd","year":"2020","unstructured":"McBane RD 2nd, Wysokinski WE, Le-Rademacher JG, et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial. J Thromb Haemost. 2020;18(2):411\u201321.","journal-title":"J Thromb Haemost"},{"issue":"17","key":"3341_CR15","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","volume":"382","author":"G Agnelli","year":"2020","unstructured":"Agnelli G, Becattini C, Meyer G, et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med. 2020;382(17):1599\u2013607.","journal-title":"N Engl J Med"},{"issue":"7","key":"3341_CR16","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1056\/NEJMoa1711948","volume":"378","author":"GE Raskob","year":"2018","unstructured":"Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018;378(7):615\u201324.","journal-title":"N Engl J Med"},{"issue":"16","key":"3341_CR17","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1200\/JCO.23.00294","volume":"41","author":"NS Key","year":"2023","unstructured":"Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update. J Clin Oncol. 2023;41(16):3063\u201371.","journal-title":"J Clin Oncol"},{"issue":"5","key":"3341_CR18","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.annonc.2022.12.014","volume":"34","author":"A Falanga","year":"2023","unstructured":"Falanga A, Ay C, Di Nisio M, et al. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline. Ann Oncol. 2023;34(5):452\u201367.","journal-title":"Ann Oncol"},{"issue":"7","key":"3341_CR19","doi-asserted-by":"publisher","first-page":"e334","DOI":"10.1016\/S1470-2045(22)00160-7","volume":"23","author":"D Farge","year":"2022","unstructured":"Farge D, Frere C, Connors JM, et al. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol. 2022;23(7):e334\u201347.","journal-title":"Lancet Oncol"},{"issue":"4","key":"3341_CR20","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","volume":"5","author":"GH Lyman","year":"2021","unstructured":"Lyman GH, Carrier M, Ay C, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021;5(4):927\u201374.","journal-title":"Blood Adv"},{"issue":"6","key":"3341_CR21","doi-asserted-by":"publisher","first-page":"e207410","DOI":"10.1001\/jamanetworkopen.2020.7410","volume":"3","author":"SR Guntupalli","year":"2020","unstructured":"Guntupalli SR, Brennecke A, Behbakht K, et al. Safety and efficacy of apixaban vs enoxaparin for preventing postoperative venous thromboembolism in women undergoing surgery for gynecologic malignant neoplasm: a randomized clinical trial. JAMA Netw Open. 2020;3(6):e207410.","journal-title":"JAMA Netw Open"},{"key":"3341_CR22","doi-asserted-by":"publisher","first-page":"107602962211325","DOI":"10.1177\/10760296221132556","volume":"28","author":"ALM Longo de Oliveira","year":"2022","unstructured":"Longo de Oliveira ALM, de Oliveira Pereira RF, Agati LB, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after major gynecological cancer surgery: the VALERIA Trial: Venous thromboembolism prophylAxis after gynecoLogical pElvic cancer surgery with RIvaroxaban versus enoxAparin (VALERIA trial). Clin Appl Thromb Hemost. 2022;28:10760296221132556.","journal-title":"Clin Appl Thromb Hemost."},{"key":"3341_CR23","doi-asserted-by":"publisher","first-page":"105906","DOI":"10.1016\/j.ijsu.2021.105906","volume":"88","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg (London, England). 2021;88:105906.","journal-title":"Int J Surg (London, England)"},{"key":"3341_CR24","doi-asserted-by":"publisher","first-page":"j4008","DOI":"10.1136\/bmj.j4008","volume":"358","author":"BJ Shea","year":"2017","unstructured":"Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ (Clinical research ed). 2017;358:j4008.","journal-title":"BMJ (Clinical research ed)"},{"issue":"11","key":"3341_CR25","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1111\/jth.13140","volume":"13","author":"S Kaatz","year":"2015","unstructured":"Kaatz S, Ahmad D, Spyropoulos AC, Schulman S. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost. 2015;13(11):2119\u201326.","journal-title":"J Thromb Haemost"},{"key":"3341_CR26","first-page":"l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ (Clinical Research ed). 2019;366:l4898.","journal-title":"BMJ (Clinical Research ed)"},{"key":"3341_CR27","first-page":"i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ (Clinical research ed). 2016;355:i4919.","journal-title":"BMJ (Clinical research ed)"},{"issue":"3","key":"3341_CR28","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177\u201388.","journal-title":"Control Clin Trials"},{"issue":"7414","key":"3341_CR29","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ (Clinical research ed). 2003;327(7414):557\u201360.","journal-title":"BMJ (Clinical research ed)"},{"issue":"7109","key":"3341_CR30","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical research ed). 1997;315(7109):629\u201334.","journal-title":"BMJ (Clinical research ed)"},{"issue":"2","key":"3341_CR31","doi-asserted-by":"publisher","first-page":"e1230","DOI":"10.1002\/cl2.1230","volume":"18","author":"NR Haddaway","year":"2022","unstructured":"Haddaway NR, Page MJ, Pritchard CC, McGuinness LA. PRISMA2020: an R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and Open Synthesis. Campbell Syst Rev. 2022;18(2):e1230.","journal-title":"Campbell Syst Rev"},{"issue":"8","key":"3341_CR32","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1002\/ajh.26945","volume":"98","author":"M Zhao","year":"2023","unstructured":"Zhao M, Bao Y, Jiang C, et al. Rivaroxaban versus nadroparin for thromboprophylaxis following thoracic surgery for lung cancer: a randomized, noninferiority trial. Am J Hematol. 2023;98(8):1185\u201395.","journal-title":"Am J Hematol."},{"key":"3341_CR33","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ygyno.2018.04.453","volume":"149","author":"A Nagy","year":"2018","unstructured":"Nagy A, Tegge AN, Borden LE, Osborne JL, Valea FA, Iglesias DA. A retrospective comparison of oral rivaroxaban versus subcutaneous low-molecular-weight heparin for postoperative thromboprophylaxis in women with a gynecologic malignancy. Gynecol Oncol. 2018;149:199\u2013200.","journal-title":"Gynecol Oncol"},{"key":"3341_CR34","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.urology.2021.04.054","volume":"156","author":"RM Ortiz","year":"2021","unstructured":"Ortiz RM, Golijanin B, O\u2019Rourke TK, et al. Direct oral anticoagulants for venous thromboembolism prophylaxis following robot-assisted radical cystectomy: a retrospective feasibility study at a single academic medical center. Urology. 2021;156:154\u201362.","journal-title":"Urology"},{"issue":"6","key":"3341_CR35","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1007\/s11605-018-3936-1","volume":"23","author":"MF Rashid","year":"2019","unstructured":"Rashid MF, Jackson TL, Morgan JA, et al. Dabigatran (Pradaxa) is safe for extended venous thromboembolism prophylaxis after surgery for pancreatic cancer. J Gastrointest Surg. 2019;23(6):1166\u201371.","journal-title":"J Gastrointest Surg"},{"key":"3341_CR36","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1111\/bju.16036","volume":"132","author":"JM Rich","year":"2023","unstructured":"Rich JM, Elkun Y, Geduldig J, et al. Outcomes from a prospectively implemented protocol using apixaban after robotic radical cystectomy. BJU Int. 2023;132:390.","journal-title":"BJU Int."},{"key":"3341_CR37","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ygyno.2023.02.012","volume":"172","author":"E Sp\u00e9nard","year":"2023","unstructured":"Sp\u00e9nard E, Geerts W, Lin Y, et al. Apixaban for extended postoperative thromboprophylaxis in gynecologic oncology patients undergoing laparotomy. Gynecol Oncol. 2023;172:9\u201314.","journal-title":"Gynecol Oncol"},{"key":"3341_CR38","doi-asserted-by":"publisher","first-page":"S239","DOI":"10.1016\/S0090-8258(21)01105-7","volume":"162","author":"M Swaroop","year":"2021","unstructured":"Swaroop M, Borden L, Locklear T, et al. Postoperative thromboprophylaxis with oral rivaroxaban versus subcutaneous low-molecular-weight heparin: a retrospective comparison in women with a gynecologic malignancy. Gynecol Oncol. 2021;162:S239.","journal-title":"Gynecol Oncol"},{"issue":"4","key":"3341_CR39","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1097\/JU.0000000000002788","volume":"208","author":"ME Westerman","year":"2022","unstructured":"Westerman ME, Bree KK, Msaouel P, et al. Apixaban vs enoxaparin for post-surgical extended-duration venous thromboembolic event prophylaxis: a prospective quality improvement study. J Urol. 2022;208(4):886\u201395.","journal-title":"J Urol"},{"issue":"1","key":"3341_CR40","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1411","volume":"12","author":"LA McGuinness","year":"2021","unstructured":"McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2021;12(1):55\u201361.","journal-title":"Res Synth Methods."},{"issue":"1","key":"3341_CR41","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1097\/SLA.0b013e31821b98da","volume":"254","author":"RP Merkow","year":"2011","unstructured":"Merkow RP, Bilimoria KY, McCarter MD, et al. Post-discharge venous thromboembolism after cancer surgery: extending the case for extended prophylaxis. Ann Surg. 2011;254(1):131\u20137.","journal-title":"Ann Surg"},{"issue":"1","key":"3341_CR42","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1001\/jamasurg.2013.3172","volume":"149","author":"VQ Trinh","year":"2014","unstructured":"Trinh VQ, Karakiewicz PI, Sammon J, et al. Venous thromboembolism after major cancer surgery: temporal trends and patterns of care. JAMA Surg. 2014;149(1):43\u20139.","journal-title":"JAMA Surg"},{"issue":"6","key":"3341_CR43","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1016\/j.jtcvs.2022.06.016","volume":"164","author":"J Kho","year":"2022","unstructured":"Kho J, Mitchell J, Curry N, Di Chiara F, Stavroulias D, Belcher E. Should all patients receive extended thromboprophylaxis after resection of primary lung cancer? J Thorac Cardiovasc Surg. 2022;164(6):1603.","journal-title":"J Thorac Cardiovasc Surg."},{"key":"3341_CR44","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.thromres.2018.02.144","volume":"173","author":"A Li","year":"2019","unstructured":"Li A, Garcia DA, Lyman GH, Carrier M. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): a systematic review and meta-analysis. Thromb Res. 2019;173:158\u201363.","journal-title":"Thromb Res"},{"key":"3341_CR45","doi-asserted-by":"publisher","first-page":"vi234","DOI":"10.1093\/annonc\/mdw371.87","volume":"27","author":"S Seo","year":"2016","unstructured":"Seo S, Ryu MH, Kang YK, et al. Oral rivaroxaban versus subcutaneous low molecular weight heparin treatment for venous thromboembolism in patients with upper gastrointestinal, hepatobiliary and pancreatic cancer. Ann Oncol. 2016;27:vi234.","journal-title":"Ann Oncol."},{"key":"3341_CR46","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.thromres.2020.06.025","volume":"194","author":"T Haykal","year":"2020","unstructured":"Haykal T, Zayed Y, Deliwala S, et al. Direct oral anticoagulant versus low-molecular-weight heparin for treatment of venous thromboembolism in cancer patients: an updated meta-analysis of randomized controlled trials. Thromb Res. 2020;194:57\u201365.","journal-title":"Thromb Res"},{"issue":"7","key":"3341_CR47","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1055\/s-0040-1712098","volume":"120","author":"M Giustozzi","year":"2020","unstructured":"Giustozzi M, Agnelli G, Del Toro-Cervera J, et al. Direct oral anticoagulants for the treatment of acute venous thromboembolism associated with cancer: a systematic review and meta-analysis. Thromb Haemost. 2020;120(7):1128\u201336.","journal-title":"Thromb Haemost"},{"issue":"5","key":"3341_CR48","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1093\/ehjcvp\/pvaa067","volume":"7","author":"A Elbadawi","year":"2021","unstructured":"Elbadawi A, Shnoda M, Mahmoud K, Elgendy IY. Efficacy and safety of direct oral anticoagulants vs. low molecular weight heparin for cancer-related venous thromboembolism: a meta-analysis of randomized trials. Eur Heart J Cardiovasc Pharmacother. 2021;7(5):380\u20138.","journal-title":"Eur Heart J Cardiovasc Pharmacother"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-024-03341-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-024-03341-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-024-03341-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T22:10:16Z","timestamp":1709244616000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-024-03341-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,26]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3341"],"URL":"https:\/\/doi.org\/10.1186\/s12957-024-03341-5","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,26]]},"assertion":[{"value":"10 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This meta-analysis has no ethical approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"69"}}